- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02155790
The Peregrine Study: A Safety and Performance Study of Renal Denervation
A Safety and Performance Study of Renal Denervation by Neurolysis Using the Ablative Solutions Inc. Peregrine System™ Infusion Catheter
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There is strong evidence in the published literature that the renal nerves are important contributors to hypertension, and that their ablation does not have adverse side-effects. The literature provides technical, clinical and scientific evidence supporting the use of perivascular renal denervation for a carefully defined patient group.
An existing device (the Ardian Symplicity catheter) has been shown to be safe and effective for achieving perivascular renal denervation by delivery of radiofrequency energy. Perivascular renal denervation by radio-frequency energy delivery is an effective therapy, associated with very low risks. In other contexts, denervation can also be safely and effectively achieved by neurolytic agents.
The objectives of the study are to evaluate the safety and performance of renal denervation by a chemical neurolytic agent delivered into the advential/ periadventitial area of the renal arteries for the purpose of neurolysis, using the Peregrine System Infusion Catheter, in patients with refractory hypertension.
The ASI Peregrine System Infusion Catheter is similar enough to the Ardian Symplicity catheter to enable the use of published data to establish the validity of the design concept of the Peregrine System and estimate the likely levels of risk from side effects. It can be concluded from the literature that the ASI Peregrine System will achieve percutaneous renal denervation with a low risk of procedural complications (comparable to accepted percutaneous interventional therapies) and without long-term impairment of renal artery or kidney function or other serious adverse events.
Chemical denervation is an appropriate treatment for the specified study population of adults who have resistant hypertension despite taking at least 3 anti-hypertensive drugs of different classes including at least one diuretic. In order for the study to be valid, only one chemical neurolytic agent can be used. The Coordinating Investigator has chosen to use dehydrated alcohol (96 - 98% by volume) for therapeutic neurolysis, therefore all participating sites will use this agent. This clinical investigation is intended to provide clinical data that demonstrates the safety and performance of the ASI Peregrine System Infusion Catheter.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patient, age 18-75, male or female;
- Patient has a clinic systolic blood pressure ≥ 160 mm Hg (or ≥ 150 mm Hg in type 2 diabetic patients) based on an average of 3 office/clinic measurements taken manually;
- Patient has a daytime mean systolic pressure ≥135 mm Hg based on 24 hours ambulatory blood pressure monitoring, with >85% valid readings.
- Patient with resistant hypertension is receiving and adhering to a stable medication regimen of at least 3 anti-hypertensive medications of different classes (for at least 4 weeks), one of which must be a diuretic. The three (or more) - medication regimen must be maximal in terms of dose and tolerability in the judgement of the investigator, such that the next step in blood pressure management would be the addition of a further medication.
- Patient has an eGFR ≥ 45 mL/min, based on the CKD-EPI equation;
- Patient has no implanted ICD, pacemaker or neurostimulator or any metallic implant which is not compatible with magnetic resonance imaging. THis is applicable to sites were MRI is planned. Implanted devices are acceptable at sites where CT will be used
Patient has optimal renal artery anatomy (no clear abnormalities) based on Investigator's evaluation of CT-angiogram/ or as alternative MR-angiogram and /or renal angiogram including:
- Single or two renal arteries, if each has a 5-7 mm diameter, respectively (accessory renal arteries are acceptable if diameter is is ≤ 2 mm, which will not be treated)
- No aneurysms
- No excessive tortuosity
- No previous stenting or balloon angioplasty of the renal arteries
- No previous renal denervation;
- Patient has provided written informed consent
Exclusion Criteria:
- Patient has known or suspected secondary hypertension;
- Patient has type 1 diabetes mellitus;
- Patient requires chronic oxygen support;
- Patient has primary or secondary pulmonary hypertension;
- Patient has a known bleeding diathesis.
- Patient has thrombocytopenia (platelet count <100,000 platelets/µL;
- Patient is pregnant or nursing or planning to become pregant;
- Patient has significant imaging-assessed renovascular abnormalities including short length main renal artery (< 10mm) and renal artery stenosis >60% of the normal diameter segment;
- Patient has history of nephrectomy, a single kidney, kidney tumor or urinary tract obstruction (with potential for hydronephrosis);
- Patient is known to have a unilateral non-functioning kidney or unequal renal size (>2 cm difference in renal length between kidneys);
- Patient has a renal transplant;
- Patient has a history of kidney stones;
- Patient has a history of heterogeneities in the kidney such as cysts or tumors;
- Patient has a history of pyelonephritis;
- Patient has a history of myocardial infarction, unstable angina pectoris, or cerebrovascular accident within the last six months;
- Patient has hemodynamically significant valvular heart disease;
- Patient has heart failure (NYHA III or IV) or has an ejection fraction ≤ 30%;
- Patient has a known allergy to contrast media;
- Patient has a life expectancy of <12 months;
- Patient is currently enrolled in other potentially confounding research, i.e., another therapeutic or interventional research trial. Patients enrolled in observational registries may still be eligible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Renal Denervation by Neurolysis
Infusion of 0.3 ml of dehydrated alcohol (96%-98%) into the peri-adventitial space of the renal artery, to achieve renal denervation by Neurolysis, via three simultaneous deployed needles, situated at the distal end of the Peregrine System Infusion Catheter.
|
The ASI catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vessel dissection or perforation
Time Frame: Immediate post procedure
|
Vessel dissection or perforation on immediate post-procedural fluoroscopy
|
Immediate post procedure
|
Grade 3 or Grade 4 hemorrhage
Time Frame: During or immediately after procedure
|
Grade 3 hemorrhage requiring transfusion or Grade 4 hemorrhage
|
During or immediately after procedure
|
Cerebrovascular accident
Time Frame: Time of procedure
|
Cerebrovascular accident at the time of procedure
|
Time of procedure
|
Myocardial infarction
Time Frame: Time of procedure
|
Myocardial infarction at the time of the procedure
|
Time of procedure
|
Sudden cardiac death
Time Frame: Time of procedure
|
Sudden cardiac death at the time of the procedure
|
Time of procedure
|
Reduction in the systolic blood pressure
Time Frame: 6 months
|
The primary performance endpoint is a reduction in the clinic systolicand diastolic blood pressure following treatment compared to baseline, assessed at 6 months.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in eGFR (reduction >25%)
Time Frame: baseline to 6 months
|
Proportion of patients with a decline in eGFR by >25% from baseline to 6 months follow-up
|
baseline to 6 months
|
New renal arterial stenosis >60%
Time Frame: 6 months
|
New renal arterial stenosis >60% from baseline confirmed by the same method used at baseline
|
6 months
|
Mean change in serum creatinine
Time Frame: post baseline visits at 7d,1 mo,3mo,6mo,12mo,24mo
|
Change in serum creatinine
|
post baseline visits at 7d,1 mo,3mo,6mo,12mo,24mo
|
Adverse events
Time Frame: post baseline visits at 7d,1 mo,3mo,6mo,12mo,24moprocedure and each of the follow-up time periods
|
Adverse events - device and non-device related
|
post baseline visits at 7d,1 mo,3mo,6mo,12mo,24moprocedure and each of the follow-up time periods
|
Changes in antihypertensive medications
Time Frame: post baseline visits at 7d,1 mo,3mo,6mo,12mo,24moeach of the follow-up visits
|
The addition of new antihypertensive drugs will be considered an intensification of the antihypertensive regimen. Discontinuation of one or more of the baseline antihypertensive medications without an increase in dose of remaining drugs or addition of new drugs will be considered a reduction in antihypertensive drug regimen. |
post baseline visits at 7d,1 mo,3mo,6mo,12mo,24moeach of the follow-up visits
|
Changes in ambulatory blood pressure measurements
Time Frame: post baseline visits at 7d,1 mo,3mo,6mo,12mo,24mo
|
Ambulatory blood pressures will be reported to determine if they follow a similar patter to the clinic blood pressures.
|
post baseline visits at 7d,1 mo,3mo,6mo,12mo,24mo
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Wojciech Wojakowski, Prof.MD.PhD, American Hospitals Poland
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ASI 12-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
Clinical Trials on The Peregrine System Infusion Catheter
-
Ablative Solutions, Inc.CompletedHypertensionBelgium, Czechia, Germany, Poland
-
Texas Tech University Health Sciences Center, El...Texas Tech University Health Sciences CenterTerminatedAnalgesia in Total Knee ArthroplastyUnited States
-
Wright State UniversitySurefire Medical, Inc.TerminatedHepatocellular Carcinoma
-
Postgraduate Institute of Medical Education and...CompletedPost-operative Analgesia | Upper Gastrointestinal Surgery | Wound Infusion Catheter | Upper Midline IncisionIndia
-
Vinmec Healthcare SystemCompletedQuality of Life | Pain, Postoperative | Opioid UseVietnam
-
Assiut UniversityCompletedAbdominal NeoplasmsEgypt
-
Centre hospitalier de l'Université de Montréal...Completed
-
Stanford UniversityCompleted
-
Princess Al-Johara Al-Ibrahim Cancer Research CenterCompletedProstatic ObstructionSaudi Arabia
-
Boston Scientific CorporationCompleted